(Q37262425)

19 August 2017

1 reference

title

Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation (English)

1 reference

19 August 2017

main subject

kidney transplantation

1 reference

1

Dela Golshayan

1 reference

19 August 2017

Manuel Pascual

2

1 reference

19 August 2017

publication date

4 September 2008

1 reference

19 August 2017

published in

Transplant Immunology

1 reference

19 August 2017

volume

20

1 reference

19 August 2017

issue

1-2

1 reference

19 August 2017

page(s)

21-28

1 reference

Update in renal transplantation

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Long-term efficacy and safety of cyclosporine in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Immunosuppression: evolution in practice and trends, 1994-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Improved graft survival after renal transplantation in the United States, 1988 to 1996

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

The natural history of chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Strategies to improve long-term outcomes after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Ten-year protocol biopsy findings of renal allografts in the calcineurin inhibitor era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Why do we reject a graft? Role of indirect allorecognition in graft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Loss of Direct and Maintenance of Indirect Alloresponses in Renal Allograft Recipients: Implications for the Pathogenesis of Chronic Allograft Nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Expansion and tissue infiltration of an allospecific CD4+CD25+CD45RO+IL-7Ralphahigh cell population in solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

The role of B cells and alloantibody in the host response to human organ allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Predicting kidney graft failure by HLA antibodies: a prospective trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Elective cyclosporine withdrawal after renal transplantation. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Elective cyclosporine withdrawal 1 year after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

The use of mycophenolate mofetil in transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

A novel approach to the treatment of chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION1,2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Chronic renal allograft dysfunction: a role for mycophenolate mofetil?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Immunosuppression minimization in pediatric transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Use of sirolimus in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Reduced exposure to calcineurin inhibitors in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Immunosuppressive preconditioning or induction regimens : evidence to date

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Drug-minimization or tolerance-promoting strategies in human kidney transplantation: is Campath-1H the way to follow?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Costimulation blockade with belatacept in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Long-term graft survival with neoral and tacrolimus: a paired kidney analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.08.006

10.1016/J.TRIM.2008.08.006

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference